{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-012540","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.406308+00:00","generated_at":"2026-05-23T09:57:25.005615+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cassava Sciences CMO retiring; new COO/Legal and SVP Clinical Dev appointed","bullets":["CMO Dr. James Kupiec retiring effective May 9, 2025.","R. Christopher Cook promoted to COO & Legal Officer from SVP/GC; base salary raised to $475,000.","Dr. Jack Moore appointed SVP Clinical Development effective April 28, 2025.","CFO Eric Schoen's employment agreement amended and restated; base salary unchanged.","Company advancing simufilam for TSC-related epilepsy after Alzheimer's program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-012540","json":"https://secwatch.observer/filing/0001437749-25-012540.json","markdown":"https://secwatch.observer/filing/0001437749-25-012540.md","text":"https://secwatch.observer/filing/0001437749-25-012540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/0001437749-25-012540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/sava20250418_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:57:25.005615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31cb1c715d","claim":"R. Christopher Cook was appointed as Chief Operating and Legal Officer at FILANA THERAPEUTICS, INC..","evidence_excerpt":"On April 18, 2025, Mr. Cook, previously our Senior Vice President and General Counsel, was appointed Chief Operating and Legal Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/0001437749-25-012540-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating and Legal Officer"}],"fact_type":"executive_change"},{"claim_id":"dc2fd3ebe8","claim":"James W. Kupiec resigned as Chief Medical Officer at FILANA THERAPEUTICS, INC..","evidence_excerpt":"On April 15, 2025, James W. Kupiec, M.D. informed Cassava Sciences, Inc. (the “Company”) of his intent to retire and tendered his resignation as the Company’s Chief Medical Officer, effective as of May 9, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/0001437749-25-012540-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}